OBR Daily Commentary - Ovarian

forumImage

Lynparza Approved In The EU For 1st-line Maintenance Treatment Of BRCA-Mutated Advanced Ovarian Cancer

(AstraZeneca) June 18, 2019 - AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of 1st-line platinum-based chemotherapy.

Howard S. Hochster, MD (Posted: June 18, 2019)

quotes For patients with germline BRCA mutations, the risk of many cancers and including breast, ovarian and pancreatic cancer are quite elevated. These tumors are sensitive to platinum based chemotherapy, and the option to use PARP inhibitors, such as olaparib, as maintenance maintenance provides a relatively non-toxic treatment option for these patients. This was also shown in the POLO study for BRCA-related pancreatic cancer with a more than doubling in PFS on maintenance. Some patients responded further by scan and these had median benefit of more than 2 years. The challenge is to extend this finding to other platinum sensitive tumors with DNA Damage Repair defects and to extend the use of these agents to more patients. quotes

Read Article arrow
Add Comment 1 Comment
forumImage

This Cancer Biotech Stock Just Averted A Patent Disaster In Europe

(Investor’s Business Daily) Dec 4, 2018 - Clovis Oncology stock surged Tuesday after a European patent decision averted a "worst case" scenario for its ovarian cancer treatment, Rubraca.

Debu Tripathy, MD (Posted: December 05, 2018)

quotesVery interesting quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...